Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy.
Xiaojia WangWei LiYongmei YinZhongsheng TongQingyuan ZhangHong ZhengZhimin ShaoHuiping LiJin YangJifeng FengFan WuFrancois LamourEleonora RestucciaZefei JiangPublished in: Translational breast cancer research : a journal focusing on translational research in breast cancer (2023)
ClinicalTrials.gov identifier: NCT03084939.